\-\ Texto\\:\\ \ \(0\)\
\-\ aphasia\\ and\\ dysarthria\ \(0\)\
\-\ radiation\\ therapy\\ as\\ these\\ tumors\\ are\\ typically\\ very\\ sensitive\\ to\\ radiation\\ therapy\\.\ \(0\)\
\-\ enhancing\\ mass\\ involving\\ left\\ orbit\\,\\ middle\\ cranial\\ fossa\\,\\ maxillary\\ sinus\\,\\ infratemporal\\ fossa\\ and\\ cavernous\\ sinus\\.\ \(0\)\
\-\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ aggressive\\ neoplasm\\:\ \(0\)\
\-\ 1\\.\\ lymphoma\\,\\ primary\\ cns\\ or\\ metastatic\\ to\\ brain\ \(0\)\
\-\ 2\\.\\ sarcoma\\,\\ primary\\ or\\ metastatic\ \(0\)\
\-\ persistent\\ headache\\ for\\ eight\\ weeks\\ and\\ mental\\ status\\ changes\\.\ \(0\)\
\-\ this\\ case\\ demonstrates\\ cns\\ lymphoma\\'s\\ ability\\ to\\ spread\\ along\\ neural\\ routes\\ and\\ brain\\ surface\\ as\\ well\\ as\\ invade\\ the\\ brain\\ parenchyma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cns\\:\\ 0\\.1474000168812196\ \(0\)\
\-\ brain\\:\\ 0\\.0866747704484077\ \(0\)\
\-\ primary\\:\\ 0\\.08532755942345044\ \(0\)\
\-\ routes\\:\\ 0\\.08347442767243379\ \(0\)\
\-\ lymphoma\\:\\ 0\\.08232130228279165\ \(0\)\
\-\ infratemporal\\:\\ 0\\.07891863994088139\ \(0\)\
\-\ fossa\\:\\ 0\\.07826516024047481\ \(0\)\
\-\ invade\\:\\ 0\\.0711304693727921\ \(0\)\
\-\ sinus\\:\\ 0\\.07022829145263905\ \(0\)\
\-\ dysarthria\\:\\ 0\\.0665746816412397\ \(0\)\
\-\ radiation\\:\\ 0\\.06301688201263678\ \(0\)\
\-\ eight\\:\\ 0\\.06288362470896963\ \(0\)\
\-\ aphasia\\:\\ 0\\.060466642915520806\ \(0\)\
\-\ ability\\:\\ 0\\.05847865743058734\ \(0\)\
\-\ maxillary\\:\\ 0\\.05249869323117939\ \(0\)\
\-\ sensitive\\:\\ 0\\.05214754105697596\ \(0\)\
\-\ therapy\\:\\ 0\\.051340242612148604\ \(0\)\
\-\ neural\\:\\ 0\\.048616652294768074\ \(0\)\
\-\ orbit\\:\\ 0\\.048366954128647735\ \(0\)\
\-\ metastatic\\:\\ 0\\.04833953715991214\ \(0\)\
\-\ aggressive\\:\\ 0\\.046975162199290585\ \(0\)\
\-\ spread\\:\\ 0\\.04644255277350875\ \(0\)\
\-\ mental\\:\\ 0\\.044800052659148284\ \(0\)\
\-\ cavernous\\:\\ 0\\.04453357483198742\ \(0\)\
\-\ as\\:\\ 0\\.043570028288566105\ \(0\)\
\-\ sarcoma\\:\\ 0\\.042751495841238676\ \(0\)\
\-\ surface\\:\\ 0\\.04238307086569945\ \(0\)\
\-\ cranial\\:\\ 0\\.041748898833059545\ \(0\)\
\-\ parenchyma\\:\\ 0\\.04089178304935583\ \(0\)\
\-\ persistent\\:\\ 0\\.03829602980344247\ \(0\)\
\-\ tumors\\:\\ 0\\.036064228737870796\ \(0\)\
\-\ middle\\:\\ 0\\.035114145726319525\ \(0\)\
\-\ very\\:\\ 0\\.03485152380288909\ \(0\)\
\-\ status\\:\\ 0\\.03427334068743431\ \(0\)\
\-\ typically\\:\\ 0\\.033892424376471594\ \(0\)\
\-\ involving\\:\\ 0\\.03368996925846397\ \(0\)\
\-\ headache\\:\\ 0\\.032977364467031436\ \(0\)\
\-\ neoplasm\\:\\ 0\\.03269838849339245\ \(0\)\
\-\ along\\:\\ 0\\.03173094243661254\ \(0\)\
\-\ 2\\.\\:\\ 0\\.03053308024494672\ \(0\)\
\-\ enhancing\\:\\ 0\\.03011183744814336\ \(0\)\
\-\ 1\\.\\:\\ 0\\.029990889508961806\ \(0\)\
\-\ changes\\:\\ 0\\.027517392991405175\ \(0\)\
\-\ weeks\\:\\ 0\\.027250311875293802\ \(0\)\
\-\ these\\:\\ 0\\.024987019010762248\ \(0\)\
\-\ or\\:\\ 0\\.022506129190195675\ \(0\)\
\-\ well\\:\\ 0\\.02172001070751293\ \(0\)\
\-\ \\'s\\:\\ 0\\.021169063127719608\ \(0\)\
\-\ case\\:\\ 0\\.021005667785025512\ \(0\)\
\-\ demonstrates\\:\\ 0\\.020973271928687483\ \(0\)\
\-\ \\,\\:\\ 0\\.015208430647038616\ \(0\)\
\-\ to\\:\\ 0\\.014395554217179312\ \(0\)\
\-\ mass\\:\\ 0\\.013353494460084995\ \(0\)\
\-\ are\\:\\ 0\\.013088470477860693\ \(0\)\
\-\ \\:\\:\\ 0\\.012699717033602977\ \(0\)\
\-\ this\\:\\ 0\\.010799294531619472\ \(0\)\
\-\ left\\:\\ 0\\.010742755834527131\ \(0\)\
\-\ for\\:\\ 0\\.00819222638924399\ \(0\)\
\-\ and\\:\\ 0\\.008090292392459257\ \(0\)\
\-\ \\.\\:\\ 0\\.0015954847684200573\ \(0\)\
\-\ the\\:\\ 0\\.0015533627494789416\ \(0\)\
